Fennec Pharmaceuticals Inc
TSX:FRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fennec Pharmaceuticals Inc
TSX:FRX
|
US |
|
Enact Holdings Inc
F:61W
|
US |
|
RB Global Inc
F:J1F
|
US |
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals is a small specialty drug company focused on one main problem in cancer care: protecting children from hearing loss caused by the chemotherapy drug cisplatin. Its lead product, PEDMARK, is a prescription treatment used alongside cisplatin for patients with certain solid tumors. The company’s business is built around developing and commercializing this medicine for hospitals, cancer centers, and pediatric oncologists that treat these patients. Fennec makes money by selling PEDMARK through the healthcare supply chain, mainly through prescription and reimbursement channels. Its customers are not typical retail buyers; they are medical providers, specialty pharmacies, and payers that help cover treatment for eligible patients. Because the product is used in a narrow clinical setting, Fennec’s role is very focused: it is not a broad oncology company with many drugs, but a single-product company centered on one supportive-care therapy. What makes Fennec’s business model different is that it sits between drug development and specialized cancer treatment. Instead of competing in crowded mass-market pharmaceuticals, it serves a defined niche where the value comes from reducing a serious side effect of chemotherapy without changing the cancer treatment itself. That makes the company dependent on physician adoption, reimbursement, and consistent use in hospitals and pediatric oncology practices.
Fennec Pharmaceuticals is a small specialty drug company focused on one main problem in cancer care: protecting children from hearing loss caused by the chemotherapy drug cisplatin. Its lead product, PEDMARK, is a prescription treatment used alongside cisplatin for patients with certain solid tumors. The company’s business is built around developing and commercializing this medicine for hospitals, cancer centers, and pediatric oncologists that treat these patients.
Fennec makes money by selling PEDMARK through the healthcare supply chain, mainly through prescription and reimbursement channels. Its customers are not typical retail buyers; they are medical providers, specialty pharmacies, and payers that help cover treatment for eligible patients. Because the product is used in a narrow clinical setting, Fennec’s role is very focused: it is not a broad oncology company with many drugs, but a single-product company centered on one supportive-care therapy.
What makes Fennec’s business model different is that it sits between drug development and specialized cancer treatment. Instead of competing in crowded mass-market pharmaceuticals, it serves a defined niche where the value comes from reducing a serious side effect of chemotherapy without changing the cancer treatment itself. That makes the company dependent on physician adoption, reimbursement, and consistent use in hospitals and pediatric oncology practices.
Sales: Net product sales were $13.8 million in Q4 2025 and $44.6 million for FY2025, up ~75% and ~50% versus the comparable 2024 periods.
Growth drivers: Management attributes growth to more treated patients, conversion improvements through the Fennec HEARS program and a targeted expansion of the field sales force focused on AYA patients.
Commercial push: Company expanded territory managers and expects those hires to ramp through 2026 with a material contribution by H2 2026.
Medical evidence: Multiple investigator-initiated studies and new real-world data (including a multi-institutional retrospective in adult head & neck cancer) are underway to support broader use beyond pediatrics.
Japan & Europe: An investigator-led PEDMARK study in Japan is progressing; Norgine launched PEDMARQSI in the U.K. and Germany in 2025 and plans 8–10 country launches in 2026.
Balance sheet & cash: Cash and cash equivalents were $36.8 million at 12/31/2025 after net equity proceeds of ~$42 million and a $21.8 million debt paydown; company now reports zero debt and expects positive cash flow in Q1 2026.
Patent settlement: Settlement with Cipla delays generic entry until September 1, 2033 (or earlier under select conditions), which management says preserves exclusivity and reduces future G&A spend.
2026 spend outlook: Cash operating expenses expected to rise from ~ $35 million in 2025 to ~ $50 million in 2026 to support commercial and medical expansion.
